Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27.
2. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.
3. Eli Lilly and Company. Lilly's Kisunla™ (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer's disease [media release]. 2 Jul 2024. https://investor.lilly.com/news-releases/news-release-details/lillys-kisunlatm-donanemab-azbt-approved-fda-treatment-early.
4. Eli Lilly and Company. KISUNLA (donanemab-azbt) injection, for intravenous use: US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf. Accessed 15 Aug 2024.
5. Gueorguieva I, Willis BA, Chua L, et al. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer’s disease. Clin Pharmacol Ther. 2023;113(6):1258–67.